Antigen-binding proteins targeting coronavirus (COV) variants

Abstract

Techniques regarding antigen-binding proteins that can bind to CoV (e.g., SARS-CoV-2) variants are provided. For example, one or more embodiments described herein can comprise an antigen-binding protein that can comprise a heavy polypeptide chain variable region with an amino acid sequence that is a variant of SEQ ID NO: 7. The amino acid sequence can comprise at least one amino acid substitution selected from the group consisting of: R50D, R50E, R50W, R50F, R50Y, R50L, R50V, R50I, R50Pho, I54D, I54E, I54W, I54F, I54Y, I54Pho, L55D, L55E, L55W, L55F, L55Y, and L55Pho.

Claims

1. An antigen-binding protein, comprising: a heavy polypeptide chain variable region with a first amino acid sequence that comprises SEQ ID NO: 10; and a light polypeptide chain variable region with a second amino acid sequence that is selected from the first group consisting of SEQ ID NO: 18 and SEQ ID NO: 19.

2. The antigen-binding protein of claim 1, wherein the heavy polypeptide chain variable region and the light polypeptide chain variable region have a binding interaction with a portion of a receptor binding domain of a variant of a SARS-CoV-2 spike protein.

3. The antigen-binding protein of claim 2, wherein the binding interaction is relative to an amino acid substitution of the receptor binding domain of the variant of the SARS-CoV-2 spike protein.

4. The antigen-binding protein of claim 3, wherein the binding interaction comprises formation of a salt-bridge.

5. The antigen-binding protein of claim 3, wherein the binding interaction comprises a cation-n interaction.

6. An antigen-binding protein, comprising: a heavy polypeptide chain variable region with a first amino acid sequence that comprises SEQ ID NO: 10; and a light polypeptide chain variable region with a second amino acid sequence that comprises SEQ ID NO: 18.

7. The antigen-binding protein of claim 6, wherein the heavy polypeptide chain variable region and the light polypeptide chain variable region have a binding interaction with a portion of a receptor binding domain of a variant of a SARS-CoV-2 spike protein.

8. The antigen-binding protein of claim 7, wherein the binding interaction is relative to an amino acid substitution of the receptor binding domain of the variant of the SARS-CoV-2 spike protein.

9. The antigen-binding protein of claim 8, wherein the binding interaction comprises formation of a salt-bridge.

10. An antigen-binding protein, comprising: a heavy polypeptide chain variable region with a first amino acid sequence that comprises SEQ ID NO: 10; and a light polypeptide chain variable region with a second amino acid sequence that comprises SEQ ID NO: 19.

11. The antigen-binding protein of claim 10, wherein the heavy polypeptide chain variable region and the light polypeptide chain variable region have a binding interaction with a portion of a receptor binding domain of a variant of a SARS-CoV-2 spike protein.

12. The antigen-binding protein of claim 11, wherein the binding interaction is relative to an amino acid substitution of the receptor binding domain of the variant of the SARS-CoV-2 spike protein.

13. The antigen-binding protein of claim 11, wherein the binding interaction comprises formation of a salt-bridge.

14. The antigen-binding protein of claim 11, wherein the binding interaction comprises a cation- interaction.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 illustrates a diagram of example, non-limiting amino acid sequences of the RBD of a SARS-CoV-2 spike protein in accordance with one or more embodiments described herein.

(2) FIG. 2 illustrates a diagram of an example, non-limiting amino acid sequence of the RBD of a SARS-CoV-2 spike protein carrying the L452R,Q amino acid substitution in accordance with one or more embodiments described herein.

(3) FIG. 3 illustrates a diagram of an example, non-limiting amino acid sequence of the RBD of a SARS-CoV-2 spike protein carrying the E484K and L452R amino acid substitutions in accordance with one or more embodiments described herein.

(4) FIG. 4 illustrates a diagram of example, non-limiting amino acid sequences of V.sub.H regions of a neutralizing antigen-binding protein with an amino acid substitution of the R50 amino acid in accordance with one or more embodiments described herein.

(5) FIG. 5 illustrates a diagram of example, non-limiting amino acid sequences of V.sub.L regions of a neutralizing antigen-binding protein with an amino acid substitution of the R96 amino acid in accordance with one or more embodiments described herein.

(6) FIG. 6 illustrates a diagram of example, non-limiting amino acid sequences of V.sub.H regions of a neutralizing antigen-binding protein with an amino acid substitution of the I54 amino acid in accordance with one or more embodiments described herein.

(7) FIG. 7 illustrates a diagram of example, non-limiting amino acid sequences of V.sub.H regions of a neutralizing antigen-binding protein with an amino acid substitution of the L55 amino acid in accordance with one or more embodiments described herein.

(8) FIG. 8 illustrates a diagram of an example, non-limiting table that can depict the binding free energy associated with various neutralizing antigen-binding proteins to demonstrate the efficacy the amino acid substitution described herein.

(9) FIG. 9 illustrates a flow diagram of an example, non-limiting method that can be employed to inhibit the activity of a CoV (e.g., SARS-CoV-2) variant carrying the E484K,Q mutation in accordance with one or more embodiments described herein.

(10) FIG. 10 illustrates a flow diagram of an example, non-limiting method that can be employed to inhibit the activity of a CoV (e.g., SARS-CoV-2) variant carrying the L452R,Q mutation in accordance with one or more embodiments described herein.

DETAILED DESCRIPTION

(11) The following detailed description is merely illustrative and is not intended to limit embodiments and/or application or uses of embodiments. Furthermore, there is no intention to be bound by any expressed or implied information presented in the preceding Background or Summary sections, or in the Detailed Description section.

(12) One or more embodiments are now described with reference to the drawings, wherein like referenced numerals are used to refer to like elements throughout. In the following description, for purposes of explanation, numerous specific details are set forth in order to provide a more thorough understanding of the one or more embodiments. It is evident, however, in various cases, that the one or more embodiments can be practiced without these specific details.

(13) As used herein, the term sequence identity can refer to the relatedness between two amino acid sequences or between two nucleotide sequences. For example, the degree of sequence identity between two amino acid sequences can be determined using the Needleman-Wunsch algorithm. As used herein, the term amino acid substitution can refer to the replacement of one amino acid in an amino acid sequence with another amino acid. In various embodiments, the following nomenclature can be employed to define an amino acid substitution: [original amino acid][position of original amino acid in the amino acid sequence][substituted amino acid]. For example, the amino acid substitution E484K can delineate a replacement of glutamic acid (E) at the 484.sup.th position of the given amino acid sequence with lysine (K). Further, amino acids can be referenced herein by their standard single letter code. Additionally, the following nomenclature can be employed to delineate an amino acid: [amino acid][position of amino acid in the amino acid sequence]. For example, the amino acid E484 can be the glutamic acid (E) at the 484.sup.th position of the given amino acid sequence. Further, where a variant comprises a combination of amino acid substitutions, a + can be located between each respective amino acid substitution. Where different amino acids can be substituted at a given position, the possible substituents can be separated by a comma. For example, R50D,E can delineate two possible amino acid substitutions: R50D or R50E. Also, as used herein, the term Pho can represent a phosphorylated residue. For instance, an amino acid substitution comprising a phosphorylated residue can comprise an amino acid phosphorylated (e.g., via a post-translational modification (PTM)). Example phosphorylated residues can include, but are not limited to: serine, threonine, and/or tyrosine.

(14) As used herein, the term coronavirus and/or CoV refers to any virus of the coronavirus family, including but not limited to SARS-CoV-2, SARS-CoV-1, and/or Mers-Cov. As used herein, the term SARS-CoV-2 refers to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a positive-sense single-stranded ribonucleic acid (RNA) virus that causes the ongoing coronavirus disease 2019 (COVID-19). SARS-CoV-2 binds via a viral spike protein to human host cell receptor angiotensin-converting enzyme 2 (ACE2). The spike protein also binds to and is cleaved by TMPRSS2, which activates the spike protein for membrane fusion of the virus. The SARS-CoV-2 spike protein is a 1273 amino acid type I membrane glycoprotein which assembles into trimers that constitute the spikes or peplomers on the surface of the enveloped coronavirus particle. Further, the spike protein binds to its cognate receptor via a receptor binding domain (RBD). The amino acid sequence of the RBD of the SARS-CoV-2 spike protein can be defined by the amino acid sequence provided in SEQ ID NO: 1.

(15) As used herein, the term coronavirus infection and/or CoV infection, can refer to infection with a coronavirus such as SARS-CoV-2, SARS-CoV-1, and/or Mers-Cov. A coronavirus infection can include coronavirus respiratory tract infections, often in the lower respiratory tract. Symptoms can include high fever, dry cough, shortness of breath, pneumonia, gastro-intestinal symptoms such as diarrhea, organ failure (e.g., kidney failure and renal dysfunction), and/or the like.

(16) As used herein, the term antibody can refer to immunoglobulin molecules comprising four polypeptide chains: two heavy polypeptide chains and two light polypeptide chains. Further, the heavy polypeptide chains can each comprise a heavy chain variable region (V.sub.H) and multiple heavy chain constant regions (C.sub.H). Likewise, the light polypeptide chains can each comprise a light chain variable region (V.sub.L) and a light chain constant regions (C.sub.L). As used herein, the term antigen-binding fragment (Fab) can refer to the variable region and constant region of the heavy polypeptide chains and light polypeptide chains that bind to a target antigen (e.g., bind to the RBD of the SARS-Cov-2 spike protein. The Fab of an antibody can comprise at least one variable region, which can be of any size or amino acid composition. In Fabs having a V.sub.H associated with a V.sub.L, the V.sub.H and V.sub.L can be situated relative to one another in any suitable arrangement. Alternatively, the Fab of an antibody can contain a monomeric V.sub.H or V.sub.L. In various embodiments, the Fab can comprise at least one variable region covalently linked to at least one constant region. Moreover, Fabs described herein can comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant region configurations. Further, in one or more embodiments, an antibody and/or Fab described herein can be conjugated to a moiety such a ligand or a therapeutic moiety (immunoconjugate) (e.g., such as an anti-viral compound, a second anti-influenza antibody, or any other therapeutic moiety useful for treating a viral infection). Moreover, in one or more embodiments, an antibody and/or Fab thereof can be, for example, a chimeric antibody, hybrid antibody and/or recombinant antibody.

(17) Various embodiments described herein can include monoclonal anti-CoV antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof) as well as monoclonal compositions comprising a plurality of isolated monoclonal antigen-binding proteins. As used herein, the term monoclonal antibody can refer to a population of substantially homogeneous antibodies. For example, the antibody molecules comprising a population of monoclonal antibodies can be substantially identical in amino acid sequence except for possible naturally occurring mutations that may be present in minor amounts.

(18) As used herein, the terms isolated antigen-binding proteins, isolated antibodies, and/or isolated Fabs can refer to polypeptides, polynucleotides and/or vectors that are at least partially free of other biological molecules from the cells or cell culture from which they are produced. Such biological molecules include nucleic acids, proteins, single-domain antibodies (e.g., NANOBODIES), other antibodies, lipids, carbohydrates, or other material such as cellular debris and growth medium. An isolated antibody and/or Fab can further be at least partially free of expression system components such as biological molecules from a host cell or of the growth medium thereof.

(19) As used herein, the term conservatively modified variant and/or a conservative substitution refers to a variant wherein there is one or more substitutions of amino acids in a polypeptide with other amino acids having similar characteristics (e.g., charge, side-chain size, hydrophobicity/hydrophilicity, backbone conformation and rigidity, etc.). Such changes can be made without significantly disrupting the biological activity of the antibody or fragment. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity. In addition, substitutions of structurally or functionally similar amino acids can be less likely to significantly disrupt biological activity. Particularly, the variable regions (e.g., V.sub.H and V.sub.L in the heavy and light chains respectively) can be less conserved than the constant regions in a Fab. For example, mutations, such as amino acid substitutions, can be observed in the variable regions of the antigen-binding protein (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof), which can allow the Fab to bind new targets. Also, as used herein, the term neutralizing anti-CoV antigen-binding protein, can refer to a molecule (e.g., an antibody, a single-domain antibody (e.g., a NANOBODY) and/or a Fab thereof) that can inhibit an activity of CoV to a detectable degree (e.g., can inhibit the ability of SARS-CoV-2 spike protein to bind to a receptor, such as ACE2).

(20) Various embodiments described herein can regard neutralizing antigen-binding proteins that can bind to the RBD of one or more variants of the CoV spike protein. For example, the RBD of the SAR-COV-2 spike protein can span from the 333.sup.rd to the 527.sup.th position of the amino acid sequence of the SAR-COV-2 spike protein and can be delineated by the amino acid sequence shown in FIG. 1 as SEQ ID NO: 1. Repetitive description of like elements employed in other embodiments described herein is omitted for the sake of brevity. A first variant of the RBD of the SAR-COV-2 spike protein can comprise at least the amino acid substitution E484K, as shown in FIG. 1 as SEQ ID NO: 2. A second variant of the RBD of the SAR-COV-2 spike protein can comprise at least the amino acid substitution E484Q, as shown in FIG. 1 as SEQ ID NO: 3. A third variant of the RBD of the SAR-COV-2 spike protein can comprise at least the amino acid substitution L452R, as shown in FIG. 2 as SEQ ID NO: 4. Repetitive description of like elements employed in other embodiments described herein is omitted for the sake of brevity. A fourth variant of the RBD of the SAR-COV-2 spike protein can comprise at least the amino acid substitution L452Q, as shown in FIG. 2 as SEQ ID NO: 5. A fifth possible variant of the RBD of the SAR-COV-2 spike protein can comprise a combination of amino acid substitutions at E484 and L452, such as at least the amino acid sequence substitutions E484K and the L452R amino acid, as shown in FIG. 3 as SEQ ID NO: 6. Repetitive description of like elements employed in other embodiments described herein is omitted for the sake of brevity. One or more embodiments described herein can comprise neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof) that can exhibit an affinity to bind to the first, second, third, fourth, and/or fifth variants of the RBD of the CoV (e.g., SAR-CoV-2) spike protein. For example, one or more embodiments described herein can comprise one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof) that can exhibit an affinity to bind to an RBD of CoV (e.g., SARS-CoV-2) spike protein having at least 50% sequence identity with SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and/or SEQ ID NO: 6.

(21) The RBD of the CoV (e.g., SARS-CoV-2) spike protein (e.g., having the amino acid sequence of SEQ ID NO: 1) can bind strongly with a Fab of the Bamlanivimab antibody through two salt bridges. For example, the Fab of Bamlanivimab can have: a V.sub.H with the amino acid sequence of SEQ ID NO: 7 (e.g., shown in FIG. 4); and/or a V.sub.L with the amino acid sequence of SEQ ID NO: 8 (e.g., shown in FIG. 5). Repetitive description of like elements employed in other embodiments described herein is omitted for the sake of brevity. The E484 amino acid in SEQ ID NO: 1 (e.g., RBD of SARS-COV-2 spike protein) can form a salt bridge with the R50 amino acid in SEQ ID NO: 7 (e.g., V.sub.H of Bamlanivimab) and the R96 amino acid in SEQ ID NO: 8 (e.g., V.sub.L of Bamlanivimab). For instance, both the R50 and R96 amino acids of Bamlanivimab can be positively charged, whereas the E484 amino acid of the RBD of the SARS-CoV-2 spike protein can be negatively charged; thereby a local electrostatic interaction can be achieved via salt bridges formed simultaneous between: the R50 amino acid of Bamlanivimab and the E484 amino acid of the RBD of the SARS-CoV-2 spike protein; and the R96 amino acid of Bamlanivimab and the E484 amino acid of the RBD of the SARS-CoV-2 spike protein.

(22) However, after the E484K,Q amino acid substitution in the RBD of a SARS-CoV-2 spike protein variant, the resulting positively charged lysine amino acid K484 or glutamine Q484 cannot coordinate with the R50 (e.g., of SEQ ID NO: 7) and/or R96 (e.g., of SEQ ID NO: 8) amino acids in the Fab of Bamlanivimab. The three positively charged residues (i.e., R50 amino acid of SEQ ID NO: 7, R96 amino acid of SEQ ID NO: 8, and K484 or Q484 amino acid of SEQ ID NO: 2, SEQ ID: 3 SEQ ID NO: 6) cannot achieve sufficient coordination due to at least electrostatic repulsion. For instance, the E484K amino acid substitution of SEQ ID NO: 2 and/or SEQ ID NO: 4 can increase the local binding free energy by, for example, 40.65 kilocalories per mol (kcal/mol); thereby destabilizing the interfacial interaction. Various embodiments described herein can regard amino acid substitutions to the Fab of Bamlanivimab (e.g., to SEQ ID NO: 7 and/or SEQ ID NO: 8) to enhance the binding affinity of the Fab of Bamlanivimab towards the K484 or Q484 amino acid of the RBD of the one or more SARS-CoV-2 spike protein variants (e.g., of SEQ ID NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 6).

(23) For example, one or more embodiments described herein can comprise amino acid substations to the Fab of Bamlanivimab (e.g., to SEQ ID NO: 7 and/or SEQ ID NO: 8) in order to: form a salt bridge with the RBD of the one or more CoV (e.g., SARS-CoV-2) spike protein variants; incorporate a hydrophobic residue into the Fab to interact with the carbon chains of the RBD of the one or more CoV (e.g., SARS-CoV-2) spike protein variants; and/or establish cation-n interactions between the Fab and the RBD of the one or more CoV (e.g., SARS-CoV-2) spike protein variants.

(24) For instance, one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof) can comprise one or more amino acid substitutions to the V.sub.H and/or V.sub.L of Bamlanivimab, substituting R50 of SEQ ID NO: 7 and/or R96 of SEQ ID NO: 8 with negatively charged aspartic acid (D) and/or glutamic acid (E). In another instance, one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof) can comprise one or more amino acid substitutions to the V.sub.H and/or V.sub.L of Bamlanivimab, substituting R50 of SEQ ID NO: 7 and/or R96 of SEQ ID NO: 8 with a hydrophobic amino acid, including, but not limited to: leucine (L), valine (V), and/or isoleucine (I). In a further instance, one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof) can comprise one or more amino acid substitutions to the V.sub.H and/or V.sub.L of Bamlanivimab, substituting R50 of SEQ ID NO: 7 and/or R96 of SEQ ID NO: 8 with tryptophan (W), phenylalanine (F), and/or tyrosine (Y) to establish cation-n interactions with the K484 or Q484 amino acid of the RBD of the one or more SARS-COV-2 spike protein variants (e.g., of SEQ ID NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 4).

(25) For example, as shown in FIG. 4, various embodiments described herein can include a neutralizing antigen-binding protein (e.g., an antibody, a single-domain antibody (e.g., a NANOBODY and/or a Fab thereof) comprising a V.sub.H with at least 50% sequence identity with SEQ ID NO: 7 and one of the following amino acid substitutions of SEQ ID NO: 7: R50D, R50E, R50W, R50F, R50Y, R50L, R50V, R50I, or R50Pho. For instance, various embodiments described herein can include a neutralizing antigen-binding protein (e.g., an antibody, a single-domain antibody (e.g., a NANOBODY and/or a Fab thereof) comprising a V.sub.H having at least at least 50% (e.g., at least 80%) sequence identity with one of the following amino acid sequences: SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16. The V.sub.L of the neutralizing antigen-binding protein can have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 8.

(26) In another example, as shown in FIG. 5, various embodiments described herein can include a neutralizing antigen-binding protein (e.g., an antibody, a single-domain antibody (e.g., a NANOBODY and/or a Fab thereof) comprising a V.sub.L with at least 50% sequence identity with SEQ ID NO: 8 and one of the following amino acid substitutions of SEQ ID NO: 8: R96D, R96E, R96W, R96F, R96Y, R96L, R96V, R96I, or R96Pho. For instance, various embodiments described herein can include a neutralizing antigen-binding protein (e.g., an antibody and/or Fab thereof) comprising a V.sub.L having at least 50% (e.g., at least 80%) sequence identity with one of the following amino acid sequences: SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24. The V.sub.H of the neutralizing antigen-binding protein can have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 7.

(27) In a further example, various embodiments described herein can include a neutralizing antigen-binding protein (e.g., an antibody, a single-domain antibody (e.g., a NANOBODY and/or a Fab thereof) comprising: a V.sub.H with at least 50% sequence identity with SEQ ID NO: 7 and one or more of the amino acid substitutions of SEQ ID NO: 7 described herein (e.g., R50D, R50E, R50W, R50F, R50Y, R50L, R50V, R50I, R50Pho); and a V.sub.L with at least 50% sequence identity with SEQ ID NO: 8 and one or more of the amino acid substitutions of SEQ ID NO: 8 described herein (e.g., R96D, R96E, R96W, R96F, R96Y, R96L, R96V, R96I, R96Pho). For instance, various embodiments described herein can include a neutralizing antigen-binding protein (e.g., an antibody, a single-domain antibody (e.g., a NANOBODY and/or a Fab thereof) comprising one of the following amino acid substitution combinations: R50D+R96D, R50D+R96E, R50D+R96W, R50D+R96F, R50D+R96Y, R50D+R96L, R50D+R96V, R50D+R96I, R50D+R96Pho, R50E+R96E, R50E+R96E, R50E+R96W, R50E+R96F, R50E+R96Y, R50E+R96L, R50E+R96V, R50E+R96I, R50E+R96Pho, R50W+R96D, R50W+R96E, R50W+R96W, R50W+R96F, R50W+R96Y, R50W+R96L, R50W+R96V, R50W+R96I, R50W+R96Pho, R50F+R96D, R50F+R96E, R50F+R96W, R50F+R96F, R50F+R96Y, R50F+R96L, R50F+R96V, R50F+R96I, R50F+R96Pho, R50Y+R96D, R50Y+R96E, R50Y+R96W, R50Y+R96F, R50Y+R96Y, R50Y+R96L, R50Y+R96V, R50Y+R96I, R50Y+R96Pho, R50L+R96D, R50L+R96E, R50L+R96W, R50L+R96F, R50L+R96Y, R50L+R96L, R50L+R96V, R50L+R96I, R50L+R96Pho, R50V+R96D, R50V+R96E, R50V+R96W, R50V+R96F, R50V+R96Y, R50V+R96L, R50V+R96V, R50V+R96I, R50V+R96Pho, R50I+R96D, R50I+R96E, R50I+R96W, R50I+R96F, R50I+R96Y, R50I+R96L, R50I+R96V, R50I+R96I, R50I+R96Pho, R50Pho+R96D, R50Pho+R96E, R50Pho+R96W, R50Pho+R96F, R50Pho+R96Y, R50Pho+R96L, R50Pho+R96V, R50Pho+R96I, R50Pho+R96Pho.

(28) Additionally, various embodiments described herein can include one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES and/or Fabs thereof) having at least 50% sequence identity with Bamlanivimab's variable domain V.sub.H (e.g., defined by SEQ ID NO: 7), and comprising one or more amino acid substitutions with regards to the I54 and/or L55 amino acids of SEQ ID NO: 7. In one or more embodiments, one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES and/or Fabs thereof) having at least 50% sequence identity with Bamlanivimab's variable domain V.sub.H (e.g., defined by SEQ ID NO: 7), and comprising one or more amino acid substitutions with regards to the I54 and/or L55 amino acids of SEQ ID NO: 7 can exhibit enhanced binding affinity for RBD variants of SARS-CoV-2 spike proteins carrying the amino acid substitution L452R,Q (e.g., for RBD of SARS-CoV-2 spike protein having the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6). For instance, after the L452R,Q mutation, the charged R452 or Q452 amino acid cannot coordinate well with the hydrophobic I54 and/or L55 amino acids.

(29) For instance, one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES and/or Fabs thereof) can comprise one or more amino acid substitutions to the V.sub.H of Bamlanivimab, substituting the I54 and/or L55 amino acids of SEQ ID NO: 7 with negatively charged aspartic acid (D) and/or glutamic acid (E). In another instance, one or more neutralizing antigen-binding proteins (e.g., antibodies and/or Fabs thereof) can comprise one or more amino acid substitutions to the V.sub.H of Bamlanivimab, substituting the I54 and/or L55 amino acids of SEQ ID NO: 7 with a negatively charged amino acid, including, but not limited to: D54, E54, D55, and/or E55. In a further instance, one or more neutralizing antigen-binding proteins (e.g., antibodies and/or Fabs thereof) can comprise one or more amino acid substitutions to the V.sub.H of Bamlanivimab, substituting the I54 and/or L55 amino acids of SEQ ID NO: 7 with tryptophan (W), phenylalanine (F), and/or tyrosine (Y) to establish cation-71 interactions with the R452 or Q452 amino acid of the RBD of the one or more SARS-CoV-2 spike protein variants (e.g., of SEQ ID NO: 4, SEQ ID NO: 5, and/or SEQ ID NO: 6).

(30) For example, as shown in FIG. 6, various embodiments described herein can include a neutralizing antigen-binding protein (e.g., an antibody, an single-domain antibody (e.g., a NANOBODY and/or a Fab thereof) comprising a V.sub.H with at least 50% sequence identity with SEQ ID NO: 7 and one of the following amino acid substitutions of SEQ ID NO: 7: I54D, I54E, I54W, I54F, I54Y, I54Pho. Repetitive description of like elements employed in other embodiments described herein is omitted for the sake of brevity. For instance, various embodiments described herein can include a neutralizing antigen-binding protein (e.g., an antibody, an single-domain antibody (e.g., a NANOBODY and/or a Fab thereof) comprising a V.sub.H having at least 50% sequence identity with one of the following amino acid sequences: SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29. The V.sub.L of the neutralizing antigen-binding protein can have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24.

(31) In another example, as shown in FIG. 7, various embodiments described herein can include a neutralizing antigen-binding protein (e.g., an antibody, an single-domain antibody (e.g., a NANOBODY and/or a Fab thereof) comprising a V.sub.H with at least 50% sequence identity with SEQ ID NO: 7 and one of the following amino acid substitutions of SEQ ID NO: 7: L55D, L55E, L55W, L55F, L55Y, L55Pho. Repetitive description of like elements employed in other embodiments described herein is omitted for the sake of brevity. For instance, various embodiments described herein can include a neutralizing antigen-binding protein (e.g., an antibody, an single-domain antibody (e.g., a NANOBODY and/or a Fab thereof) comprising a V.sub.H having at least 50% sequence identity with one of the following amino acid sequences: SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 34. The V.sub.L of the neutralizing antigen-binding protein can have an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24.

(32) In a further example, various embodiments described herein can include a neutralizing antigen-binding protein (e.g., an antibody, a single-domain antibody (e.g., a NANOBODY and/or a Fab thereof) comprising a V.sub.H with a combination of two or more of the amino acid substitutions of SEQ ID NO: 7 described herein. For instance, various embodiments described herein can include one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof) having at least 50% sequence identity with SEQ ID NO: 7, and comprising one of the following amino acid substitution combinations: I54D+L55D, I54D+L55E, I54D+L55W, I54D+L55F, I54D+L55Y, I54D+L55Pho, I54E+L55D, I54E+L55E, I54E+L55W, I54E+L55F, I54E+L55Y, I54E+L55Pho, I54W+L55D, I54W+L55E, I54W+L55W, I54W+L55F, I54W+L55Y, I54W+L55Pho, I54F+L55D, I54F+L55E, I54F+L55W, I54F+L55F, I54F+L55Y, I54F+L55Pho, I54Y+L55D, I54Y+L55E, I54Y+L55W, I54Y+L55F, I54Y+L55Y, I54Y+L55Pho, I54Pho+L55D, I54Pho+L55E, I54Pho+L55W, I54Pho+L55F, I54Pho+L55Y, or I54Pho+L55Pho. In another instance, various embodiments described herein can include one or more neutralizing antigen-binding proteins (e.g., antibodies and/or Fabs thereof) having at least 50% sequence identity with SEQ ID NO: 7, and comprising one of the following amino acid substitution combinations: R50D+L55D, R50D+L55E, R50D+L55W, R50D+L55F, R50D+L55Y, R50D+L55Pho, R50E+L55D, R50E+L55E, R50E+L55W, R50E+L55F, R50E+L55Y, R50E+L55Pho, R50W+L55D, R50W+L55E, R50W+L55W, R50W+L55F, R50W+L55Y, R50W+L55Pho, R50F+L55D, R50F+L55E, R50F+L55W, R50F+L55F, R50F+L55Y, R50F+L55Pho, R50Y+L55D, R50Y+L55E, R50Y+L55W, R50Y+L55F, R50Y+L55Y, R50Y+L55Pho, R50Pho+L55D, R50Pho+L55E, R50Pho+L55W, R50Pho+L55F, R50Pho+L55Y, R50L+L55D, R50L+L55E, R50L+L55W, R50L+L55F, R50L+L55Y, R50V+L55D, R50V+L55E, R50V+L55W, R50V+L55F, R50V+L55Y, R50I+L55D, R50I+L55E, R50I+L55W, R50I+L55F, R50I+L55Y. In a further instance, various embodiments described herein can include one or more neutralizing antigen-binding proteins (e.g., antibodies and/or Fabs thereof) having at least 50% sequence identity with SEQ ID NO: 7, and comprising one of the following amino acid substitution combinations: I54D+R50D, I54D+R50E, I54D+R50W, I54D+R50F, I54D+R50Y, I54D+R50Pho, I54E+R50D, I54E+R50E, I54E+R50W, I54E+R50F, I54E+R50Y, I54E+R50Pho, I54W+R50D, I54W+R50E, I54W+R50W, I54W+R50F, I54W+R50Y, I54W+R50Pho, I54F+R50D, I54F+R50E, I54F+R50W, I54F+R50F, I54F+R50Y, I54F+R50Pho, I54Y+R50D, I54Y+R50E, I54Y+R50W, I54Y+R50F, I54Y+R50Y, I54Y+R50Pho, I54Pho+R50D, I54Pho+R50E, I54Pho+R50W, I54Pho+R50F, I54Pho+R50Y, or I54Pho+R50Pho. In an additional instance, various embodiments described herein can include one or more neutralizing antigen-binding proteins (e.g., antibodies and/or Fabs thereof) having at least 50% sequence identity with SEQ ID NO: 7, and comprising a combination of three amino acid substitutions of SEQ ID NO: 5 in accordance with: R50D,E,W,F,Y,Pho,L,V,I+I54D,E,W,F,Y,Pho+L55D,E,W,F,Y,Pho (e.g., such as R50D+I54D+L55D). Moreover, in each of the instances described above, the one or more neutralizing antigen-binding proteins can comprise a V.sub.L having the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24.

(33) One or more embodiments described herein can include one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof) comprising: a V.sub.H with an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 10 (e.g., comprising the amino acid substitution R50E of SEQ ID NO: 7), and a V.sub.L with an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 18 (e.g., comprising the amino acid substitution R96E of SEQ ID NO: 8). For example, the K484 amino acid of the RBD variant of SARS-CoV-2 spike protein having SEQ ID NO: 2 or SEQ ID NO: 6 (e.g., carrying the E484K amino acid substitution) can form a first salt bridge with the E50 amino acid (e.g., comprised within the V.sub.H) and/or a second salt bridge with the E96 amino acid (e.g., comprised within the V.sub.L) of the one or more neutralizing antigen-binding proteins (e.g., antibodies and/or Fabs thereof). At least because the E50 and E96 amino acids of the neutralizing antigen-binding protein can be negatively charged, the K484 amino acid of the RBD of the SARS-CoV-2 spike protein can electrostatically favor the interaction with the E50 and E96 amino acids.

(34) Table 1, shown in FIG. 8, depicts protein-protein interaction energies calculated via molecular mechanics-generalized Born surface area (MMGBSA). Repetitive description of like elements employed in other embodiments described herein is omitted for the sake of brevity. In Table 1: RBD-E484 (WT) represents a SARS-CoV-2 spike protein comprising an RBD with the amino acid sequence of SEQ ID NO: 1; RBD-K484 represents a SARS-CoV-2 spike protein comprising an RBD with the amino acid sequence of SEQ ID NO: 2; and Bamlanivimab-EE represents an antigen-binding protein (e.g., a variant of Bamlanivimab) comprising a V.sub.H with an amino acid sequence having at least 50% sequence identity with of SEQ ID NO: 10 (e.g., comprising the amino acid substitution R50E of SEQ ID NO: 7), and a V.sub.L with an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 18 (e.g., comprising the amino acid substitution R96E of SEQ ID NO: 8) in accordance with various embodiments described herein. As shown in Table 1, the binding free energy for a complex of Bamlanivimab and the SARS-CoV-2 spike protein comprising a RBD having the amino acid sequence of SEQ ID NO: 1 can be 157.87 kcal/mol. However, after the E484K mutation, the binding free energy can increase to 108.24 kcal/mol (e.g., suggesting that the interfacial interaction is substantially weakened. In contrast, the binding free energy for a complex of an antigen-binding protein (e.g., a variant of Bamlanivimab) comprising a V.sub.H with an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 10 (e.g., comprising the amino acid substitution R50E of SEQ ID NO: 7), and a V.sub.L with an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 18 (e.g., comprising the amino acid substitution R96E of SEQ ID NO: 8) and the SARS-CoV-2 spike protein carrying the E484K mutation can be 156.79 kcal/mol; thereby demonstrating that the various neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof) can achieve a binding affinity towards the SARS-CoV-2 variant that is comparable to that between Bamlanivimab and the RBD of the SARS-CoV-2 nonvariant.

(35) One or more embodiments described herein can include one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof) comprising: a V.sub.H with an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 10 (e.g., comprising the amino acid substitution R50E of SEQ ID NO: 7), and a V.sub.L with an amino acid sequence having at least 50% sequence identity with SEQ ID NO: 19 (e.g., comprising the amino acid substitution R96W of SEQ ID NO: 8). For example, the K484 amino acid of the RBD variant of SARS-CoV-2 spike protein having SEQ ID NO: 2 or SEQ ID NO: 6 (e.g., carrying the E484K amino acid substitution) can form a salt bridge with the E50 amino acid (e.g., comprised within the V.sub.H) and/or favorable cation-71 interactions with the W96 amino acid (e.g., comprised within the V.sub.L) of the one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof).

(36) In one or more embodiments, the various neutralizing antigen-binding proteins described herein can be isolated antibodies. In various embodiments, the V.sub.H and/or V.sub.L regions described herein can be conservatively modified variants of the example amino acid sequences. For example, conservatively modified variants of SEQ ID NO: 9-SEQ ID NO: 34. Additionally, in accordance with the various embodiments described herein, the various neutralizing antigen-binding proteins described herein can be included in one or more therapeutic compounds. For example, the one or more neutralizing antigen-binding proteins can be included in a composition with a pharmaceutically acceptable carrier and/or other therapeutic agent (e.g., an anti-inflammatory agent, an antibody that binds to TMPRSS2, and/or an antibody that binds to the SARS-CoV-2 spike protein). In another example, the one or more neutralizing antigen-binding proteins described herein can be included in one or more combination therapies (e.g., therapies that further include Bamlanivimab, remdesivir, and/or dexamethasone).

(37) FIG. 9 illustrates a flow diagram of an example, non-limiting method 900 that can facilitate treating a CoV infection with one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof) in accordance with one or more embodiments described herein. Repetitive description of like elements employed in other embodiments described herein is omitted for the sake of brevity. In various embodiments, method 900 can be employed to facilitate treatment of a CoV infection comprising SARS-CoV-2 carrying the E484K,Q mutation.

(38) At 902, the method 900 can comprise contacting one or more antigen-binding proteins with the RBD of a SARS-CoV-2 spike protein variant carrying the E484K,Q mutation. For example, the RBD of the SARS-CoV-2 spike protein variant can have the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 6. In various embodiments, the one or more antigen-binding proteins can comprise a variant of Bamlanivimab's V.sub.H and/or V.sub.L regions, and can comprise one or more amino acid substitutions of the R50, I54, L55, and/or R96 amino acids in accordance with various embodiments described herein. For instance, the one or more antigen-binding proteins can be a variant of Bamlanivimab's V.sub.H and/or V.sub.L regions comprising one or more amino acid substitutions of the R50 and/or R96 amino acids with: one or more negatively charged amino acids (e.g., D and/or E), one or more hydrophobic residues (e.g., L, V, and/or I), one or more phosphorylated residues (e.g., serine, threonine, or tyrosine), and/or one or more molecules (e.g., amino acids W, F, and/or Y) that can establish cation-71 interactions with the RBD.

(39) In various embodiments, the contacting at 902 can be facilitated by administering an effective concentration (e.g., 35 milligrams per milliliter (mg/mL)) of the one or more antigen-binding proteins to a patient inflicted with a CoV infection. For example, the one or more antigen-binding proteins can be included in one or more therapeutic compositions (e.g., comprising a pharmaceutically acceptable carrier) that can be injected into the patient via a needle.

(40) At 904, the method 900 can comprise inhibiting the ability of the SARS-CoV-2 spike protein variant from binding to a receptor. For example, the one or more antigen-binding proteins can inhibit the SARS-CoV-2 spike protein variant from binding to receptor ACE2. For instance, the one or more antigen-binding proteins can form one or more salt bridges with the RBD of the SARS-CoV-2 spike protein variant to facilitate the inhibiting at 904. In another instance, one or more hydrophobic residues of the one or more antigen-binding proteins can interact with one or more carbon chains of K484 in the RBD of the SARS-CoV-2 spike protein variant to facilitate the inhibiting at 904. In a further instance, the one or more antigen-binding proteins can form one or more cation-n interactions with the RBD of the SARS-CoV-2 spike protein variant to facilitate the inhibiting at 904.

(41) FIG. 10 illustrates a flow diagram of an example, non-limiting method 1000 that can facilitate treating a CoV infection with one or more neutralizing antigen-binding proteins (e.g., antibodies, single-domain antibodies (e.g., NANOBODIES) and/or Fabs thereof) in accordance with one or more embodiments described herein. Repetitive description of like elements employed in other embodiments described herein is omitted for the sake of brevity. In various embodiments, method 1000 can be employed to facilitate treatment of a CoV infection comprising SARS-CoV-2 carrying the L452R,Q mutation.

(42) At 1002, the method 1000 can comprise contacting one or more antigen-binding proteins with the RBD of a SARS-CoV-2 spike protein variant carrying the L452R,Q mutation. For example, the RBD of the SARS-CoV-2 spike protein variant can have the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 6. In various embodiments, the one or more antigen-binding proteins can be a variant of Bamlanivimab's V.sub.H and/or V.sub.L regions (e.g., be a variant of Bamlanivimab), and can comprise one or more amino acid substitutions of the R50, I54, L55, and/or R96 amino acids in accordance with various embodiments described herein. For instance, the one or more antigen-binding proteins can comprise variant of Bamlanivimab's V.sub.H and/or V.sub.L regions (e.g., be a variant of Bamlanivimab) comprising one or more amino acid substitutions of the I54, L55, and/or R96 amino acids with: one or more negatively charged amino acids (e.g., D and/or E), one or more hydrophobic residues (e.g., L, V, or I), one or more phosphorylated residues (e.g., serine, threonine, or tyrosine), and/or one or more molecules (e.g., amino acids W, F, and/or Y) that can establish cation-n interactions with the RBD.

(43) In various embodiments, the contacting at 1002 can be facilitated by administering an effective concentration (e.g., 35 milligrams per milliliter (mg/mL)) of the one or more antigen-binding proteins to a patient inflicted with a CoV infection. For example, the one or more antigen-binding proteins can be included in one or more therapeutic compositions (e.g., comprising a pharmaceutically acceptable carrier) that can be injected into the patient via a needle.

(44) At 1004, the method 1000 can comprise inhibiting the ability of the SARS-CoV-2 spike protein variant from binding to a receptor. For example, the one or more antigen-binding proteins can inhibit the SARS-CoV-2 spike protein variant from binding to receptor ACE2. For instance, the one or more antigen-binding proteins can form one or more salt bridges with the RBD of the SARS-CoV-2 spike protein variant to facilitate the inhibiting at 1004. In another instance, one or more hydrophobic residues of the one or more antigen-binding proteins can interact with one or more carbon chains of the RBD of the SARS-CoV-2 spike protein variant to facilitate the inhibiting at 1004. In a further instance, the one or more antigen-binding proteins can form one or more cation-n interactions with the RBD of the SARS-CoV-2 spike protein variant to facilitate the inhibiting at 1004.

(45) In addition, the term or is intended to mean an inclusive or rather than an exclusive or. That is, unless specified otherwise, or clear from context, X employs A or B is intended to mean any of the natural inclusive permutations. That is, if X employs A; X employs B; or X employs both A and B, then X employs A or B is satisfied under any of the foregoing instances. Moreover, articles a and an as used in the subject specification and annexed drawings should generally be construed to mean one or more unless specified otherwise or clear from context to be directed to a singular form. As used herein, the terms example and/or exemplary are utilized to mean serving as an example, instance, or illustration. For the avoidance of doubt, the subject matter disclosed herein is not limited by such examples. In addition, any aspect or design described herein as an example and/or exemplary is not necessarily to be construed as preferred or advantageous over other aspects or designs, nor is it meant to preclude equivalent exemplary structures and techniques known to those of ordinary skill in the art.

(46) It is, of course, not possible to describe every conceivable combination of components, products and/or methods for purposes of describing this disclosure, but one of ordinary skill in the art can recognize that many further combinations and permutations of this disclosure are possible. Furthermore, to the extent that the terms includes, has, possesses, and the like are used in the detailed description, claims, appendices and drawings such terms are intended to be inclusive in a manner similar to the term comprising as comprising is interpreted when employed as a transitional word in a claim. The descriptions of the various embodiments have been presented for purposes of illustration, but are not intended to be exhaustive or limited to the embodiments disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The terminology used herein was chosen to best explain the principles of the embodiments, the practical application or technical improvement over technologies found in the marketplace, or to enable others of ordinary skill in the art to understand the embodiments disclosed herein.